ClinicalTrials.gg
RecruitingNCT07597174Updated May 22, 2026

Mobile App vs. In-Person Pelvic Floor Rehabilitation for Urinary Leakage in Adult Women

An interventional study of Mobile app based rehabilitation protocol and Presential rehabilitation program in Urinary Incontinence , Stress, sponsored by Unidade Local de Saúde São João. Recruiting at 1 site in Portugal. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Unidade Local de Saúde São João · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The goal of this clinical trial is to learn if a mobile app-guided pelvic floor rehabilitation program works as well as standard in-person pelvic floor rehabilitation to treat urinary leakage in adult women.

The main question it aims to answer is:

Does the app program improve quality of life related to urinary leakage as much as in-person rehabilitation?

Researchers will compare the app-based program to in-person rehabilitation to see if both lead to similar improvements in quality of life.

Participants will:

Attend one medical visit before starting to confirm they are eligible Attend one in-person training session with a physiotherapist Follow either an app-based or an in-person pelvic floor rehabilitation program for 3 months Complete quality of life questionnaires at the start and at 4 months

Read the detailed description

Background

Urinary incontinence (UI) is common in women and undertreated in Portugal. Only 11% of Portuguese women with UI report having completed any rehabilitation program. Conventional pelvic floor rehabilitation requires supervised sessions two to three times per week for at least 3 to 4 months, mostly available only at tertiary hospitals. Mobile app-based programs may improve access, adherence, and convenience. However, no randomized trial has compared an app-based program directly against supervised rehabilitation as an active comparator in the Portuguese population. An important consideration in participant selection is pelvic floor muscle function. Studies show that up to 53% of women with UI cannot contract the pelvic floor correctly without prior in-person training. For this reason, the ability to voluntarily contract the pelvic floor is an inclusion criterion, confirmed at the baseline medical visit.

Study Design

This is a randomized controlled non-inferiority trial with two parallel arms conducted at the Pelvic Floor Rehabilitation Unit of the Physical and Rehabilitation Medicine (PM\&R) Department of ULS São João, a tertiary academic hospital in Porto, Portugal.

The Mobile App

The app-based program was developed by the investigators in collaboration with the Information Systems and Technologies Department and the Data Intelligence Department of ULS São João. It was integrated into the existing My São João App, a platform already in use by patients of the hospital. Prior to the trial, a preliminary version was tested over one month with 10 women with prior experience in supervised pelvic floor rehabilitation and with 4 clinicians specialised in pelvic floor rehabilitation. Participants completed a structured questionnaire assessing interface usability, aesthetics, engagement, and functionality, and took part in a discussion of weaknesses and suggestions for improvement. A final version was developed based on this feedback.

Randomization

After baseline assessment, participants are randomized 1:1 into the intervention or control group by a research assistant not involved in the investigation. Allocation uses a computer-generated random sequence implemented through sequentially numbered sealed opaque envelopes, stored in a locked cabinet accessible only to the research assistant. Envelopes are opened immediately before the initial individual session. Participants and health professionals are not blinded to group allocation.

Intervention Group - App-Based Program (12 weeks)

One in-person medical consultation at the start. Participants install the app, are trained on its use, and receive lifestyle and behavioural recommendations tailored to their UI type and baseline assessment results. Three in-person individual physiotherapy sessions at weeks 0, 4, and 8. At each session, participants are trained on the exercises that will be released on the app following that session. App content includes a structured pelvic floor muscle exercise program released in 3 progressive phases, with gradual increases in duration, repetitions, and positions. Participants perform a daily sequence 3 times per day and two 30-minute sessions per week. Programmable reminders allow participants to set exercise times according to their own schedule. Daily app notifications collect feedback on the number of sessions completed and participant satisfaction. One teleconsultation at week 6 to assess adherence, motivation, side effects, and progress. At week 12, participants are notified via the app to begin the maintenance phase: the daily sequence 3 times per day, 3 days per week. One in-person medical consultation at week 16 to assess compliance and outcomes.

Control Group - Supervised Program (12 weeks)

One in-person medical consultation at the start. Participants receive lifestyle and behavioural recommendations tailored to their UI type and baseline assessment results, and a written leaflet with a pelvic floor exercise sequence to perform 3 times per day. One initial in-person individual physiotherapy session, followed by supervised face-to-face group sessions twice per week (30 minutes each), structured in 3 progressive phases matching those of the app program. One in-person medical consultation at week 6 to assess adherence, side effects, and progress. At week 12, participants are instructed to begin the maintenance phase: 3 exercise sets, 3 days per week. One in-person medical consultation at week 16 to reassess compliance and outcomes.

Assessment Schedule

Outcomes are collected by physiatrists specialised in pelvic floor rehabilitation using a digital data collection form at three time points: baseline (week 0), mid-program (week 6), and end of follow-up (week 16).

Sample Size

Sample size was calculated using WinPepi version 11.65, assuming a significance level of 5%, statistical power of 80%, and a 1:1 allocation ratio. Based on a non-inferiority margin of 10.24 points on the King's Health Questionnaire (KHQ), with standard deviations of 10.545 (intervention) and 6.23 (control), 24 participants are required (12 per group). Accounting for an estimated 33% dropout rate, the target sample is 32 participants.

Statistical Analysis

Continuous variables will be described as means with standard deviations, or medians with interquartile ranges, depending on distribution. Categorical variables will be presented as proportions. Between-group comparisons at end of program will use the independent-samples t-test for normally distributed data, or the Mann-Whitney test otherwise. Categorical variables will be compared using the Chi-square or Fisher's exact test as appropriate. A pre-specified subgroup analysis will examine adherence and clinical improvement according to age, primary diagnosis (SUI or MUI), prior treatments, condition severity, quality of life scores, marital status, educational level, profession, smartphone operating system, duration of smartphone ownership, daily hours of use, and prior experience with health-related apps. A subsequent cost-effectiveness analysis is planned.

Ethical Considerations

The study is conducted in accordance with the ethical principles of the 1964 Declaration of Helsinki and its subsequent amendments. Participation is voluntary. Eligible participants are approached at their first consultation and given a participant information sheet and written informed consent form to take home. Signed consent is confirmed at the second appointment, two weeks later. Participants may withdraw at any time without consequence. All data are anonymised prior to analysis and stored securely with password protection. Only the participant's physiatrist has access to medical records. Results will be disseminated at scientific conferences and in peer-reviewed journals.

02

Conditions studied

  • Urinary Incontinence , Stress

Keywords

  • mobile app
  • urinary incontinence
  • woman
03

In context

Urinary Incontinence, Stress

655 studies on the registry are indexed under Urinary Incontinence, Stress; 123 are open to participants now.

This study's planned enrollment of 32 is below the median of 68 across 510 interventional studies indexed under Urinary Incontinence, Stress.

Browse Urinary Incontinence, Stress studies →

Lead sponsor

Unidade Local de Saúde São João is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age >18 years
  • stress urinary incontinence (SUI) or mixed urinary incontinence with predominance of SUI
  • more than one urinary incontinence episode for week in the last month
  • pelvic floor muscle strength equal or greater than 2 assessed by Oxford Modified Rating Score

Exclusion criteria

Exclusion Criteria:

  • indwelling urinary catheter
  • active pelvic neoplasia
  • pelvic organ prolapse grade greater than or equal to 2
  • active urinary tract infection or macroscopic hematuria
  • neurogenic dysfunction of the lower urinary tract
  • cognitive deficit, osteoarticular, neurological or psychiatric pathologies that prevent the realization of the therapeutic program
  • conservative or surgical treatment of UI in the last 12 months
  • pregnancy or recent childbirth (\< 6 months)
  • impossibility of access or illiteracy to technological means (smartphone)
  • unavailability to attend the supervised program due to accessibility, schedule or economic reasons
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Hybrid

    mobile app based treatment

    Other: Mobile app based rehabilitation protocol

  • Active comparator
    conventional

    presential

    Other: Presential rehabilitation program

Interventions

  • OtherMobile app based rehabilitation protocol

    Mobile app based rehabilitation protocol for Stress and Mixed Urinary Incontinence in Adult Women

  • OtherPresential rehabilitation program

    Presential rehabilitation program for Stress and Mixed Urinary Incontinence in Adult Women

06

What researchers measure

Primary outcomes

  1. UI-related quality of life

    UI-related quality of life using the Portuguese version of the King´s Health Questionnaire (KHQ). KHQ is a disease-specific, self-administered questionnaire designed to assess the impact of UI on quality of life in women. The responses in KHQ have a four point rating system. The eight subscales ("domains") score between 0 (best) and 100 (worst). The Symptom Severity scale is scored from 0 (best) to 30 (worst). Decreases in KHQ domain scores indicate an improvement in quality of life. The minimally important difference - the smallest change in score that subjects perceive as beneficial - is 3 points for the symptom severity scale and 5 points for all other KHQ domains.

    Time frame: At baseline and in16 weeks

Secondary outcomes

  1. UI severity

    UI severity using: the ICS pad test, the Portuguese versions of the ICIQ-bladder diary, and of the International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF). The ICS pad test has been standardized by the International Continence Society and implies drinking 500mL of water and performing a protocol of activities during 1 hour. The total amount of urine leaked is determined by weighing the pad at the end. A weight difference of 1g is considered as significative. The ICIQ-bladder diary is a standardised diary that includes records of the number of incontinence episodes. The ICIQ-UI Short Form is a self-administered questionnaire for evaluating the frequency, severity and impact on quality of life of UI. It contains 4 items: frequency of urinary incontinence; amount of leakage; overall impact of urinary incontinence; self-diagnostic item. It is scored from 0 (best) to 21 (worst), considering 2.5 points for a minimal clinically important difference.

    Time frame: At baseline and in16 weeks

  2. Perception of change

    Perception of change by the patient using the Portuguese version of the Patient Global Impression of Change (PGIC) Scale. The PGIC Scale is is a global index that may be used to rate the response of a condition to a therapy. It is a transition scale consisting of a single question asking the patient to rate their urinary tract condition now, as compared with how it was prior to beginning treatment on a scale from 1 (Very much better) to 7 (Very much worse).

    Time frame: At baseline and in16 weeks

  3. Sexual function

    Sexual function using the Portuguese version of the Female Sexual Functioning Index (FSFI). The FSFI is a survey measuring the sexual functioning of women over the previous 30 days in six different domains: desire, arousal, lubrication, orgasm, satisfaction and pain. Sexual disfunction severity is classified into five categories based on FSFI total scores: severe (2-7.2), moderate (7.3-14.4), mild to moderate (14.5-21.6), mild (21.7-28.1 "cutoff value"), and no sexual disfunction (28.2-36).

    Time frame: At baseline and in16 weeks

  4. Symptoms of depression/anxiety

    Symptoms of depression/anxiety using the Portuguese version of the Hospital Anxiety \& Depression Scale (HADS) questionnaire. HADS is a fourteen-item scale with seven items each for anxiety and depression subscales. Scoring for each item ranges from zero to three. A subscale score \>8 denotes anxiety or depression.

    Time frame: At baseline and in 16 weeks

  5. Health related quality of life

    Health related quality of life, using the Portuguese version of the EuroQol 5-Dimension 5-level (EQ-5D-5L) questionnaire. The EQ-5D-5L is a brief, generic, health status measure composed of 5 questions with Likert response options (descriptive system) and a visual analog scale (EQ-VAS). The latter asks patients to rate their own health from 0 to 100 (the worst and best imaginable health, respectively). The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement. EQ-5D utility values can be used to calculate QALYs, which can then be used in cost-utility analysis.

    Time frame: At baseline and in 16 weeks

  6. Satisfaction and adherence to treatment .

    Satisfaction and adherence to treatment using a 9-point Likert scale and the self-reported number of performed sessions registered in the app (intervention group) and reported by the therapist (control group).

    Time frame: At 16 weeks

  7. Participants assessment of the app quality

    Participants assessment of the app quality using the Portuguese version of the User Mobile App Rating Scale (uMARS). The uMARS provides 20 items in a total of 5 subscales, 4 objective quality subscales - Engagement, Functionality, Aesthetics and Information Quality - and 1 subjective quality subscale that adds 6 items to measure the impact perceived by users of the evaluated application. All items are rated on a 5-point scale from "1. Inadequate" to "5. Excellent"; there is an option to select "N/A" if the application component is irrelevant. The quality score is calculated as follows: App Quality Mean Score = (A+B+C+D)/4, where A: Engagement Mean Score; B: Functionality Mean Score; C: Aesthetics Mean Score; D: Information Mean Score. Questions rated "N/A" are excluded from the mean score calculation. Total mean score reflects the overall app quality, higher scores indicate a better user experience.

    Time frame: 16 weeks

  8. Direct costs of urinary incontinence

    Direct costs of urinary incontinence with an adapted version of the Dowell-Bryant Incontinence Cost Index (DBICI). The DBICI gives a detailed measure of the direct economic costs of urinary incontinence in ambulatory home-dwelling women, with the construct validity confirmed by the significant correlation with other quantitative measures of incontinence. By substituting local prices into the test format, the index can be used in different countries.

    Time frame: At baseline and in16 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Aug 2026, 4 months after the start.

Of 227 non-industry interventional studies with no phase under Urinary Incontinence, Stress, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 4 months is below that.

Counting every sponsor, half of 268 studies reached it within 19 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 19, 2026
StartActual
Mar 26, 2026
Primary completionEst.
Aug 21, 2026
CompletionEst.
Aug 21, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07597174
Lead sponsor
Unidade Local de Saúde São João
Responsible party
Susana Moreira (Principal investigator, Unidade Local de Saúde São João) — Principal investigator
First posted
May 19, 2026
Start date
Mar 26, 2026
Primary completion
Aug 21, 2026 (estimated)
Completion
Aug 21, 2026 (estimated)
Last update
May 22, 2026

Study contacts

Susana A Moreira, PMR specialist
Contact
s.moreira@ulssjoao.min-saude.pt
+351917210578

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion